Nektar Therapeutics (NKTR) Share-based Compensation (2010 - 2026)

Nektar Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 13.93% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $12.1 million (down 37.95% YoY), while the FY2025 annual figure was $12.6 million, down 41.47% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.4 million, up from $2.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $21.0 million in Q1 2022, with the low at $2.2 million in Q4 2025.
• The 5-year median for Share-based Compensation is $6.0 million (2024), against an average of $7.5 million.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation slipped 12.29% in 2022, then sank 54.34% in 2025.
• Nektar Therapeutics' Share-based Compensation stood at $12.7 million in 2022, then slumped by 43.05% to $7.3 million in 2023, then sank by 33.79% to $4.8 million in 2024, then tumbled by 54.34% to $2.2 million in 2025, then surged by 52.99% to $3.4 million in 2026.
• Business Quant data shows NKTR's Share-based Compensation at $3.4 million in Q1 2026, $2.2 million in Q4 2025, and $3.1 million in Q3 2025.